gil yosipovitch: Live & Latest News Updates : Vimarsana.com

Neuropeptide in Blood to Help Diagnose Chronic Itch

B-type natriuretic peptide (BNP) plays a key role in chronic itch severity and can help to identify certain types of itch with a simple blood test, according t

Why we may be hardwired to shun those who scratch

We derive pleasure from scratching an itch – but may have evolved to shun those who scratch.

The new drugs that may bring an end to constant itching

While for most people, an itch is an annoying, temporary nuisance, one in five of us will experience chronic itch lasting weeks or months. New treatments finally offer hope.

Gil Yosipovitch, MD: Overview of Current Research on Prurigo Nodularis

During this interview segment, Dr. Yosipovitch discussed his overview of current PN research and a specific study he had presented at EADV.

Gil Yosipovitch, MD: New Analysis of Data on Patient Satisfaction with Dupilumab for Prurigo Nodularis

This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.

Why It Can Feel Impossible to Stop Scratching an Itch

There’s a reason it feels so maddeningly good.

Why can't you stop scratching an itch?

There’s a reason it feels so maddeningly good.

Adults, children with chronic spontaneous urticaria differ in clinical features, response

Pediatric and adult chronic spontaneous urticaria exhibit distinct features, with adolescent presentations resembling those of adults more than those of younger children, according to a study published in Pediatric Allergy and Immunology. Younger children with chronic spontaneous urticaria (CSU) also have better responses to antihistamines than adolescents and adults, suggesting more severe and

Pierre Fabre Compiles 3.3 Million Skin-related Data Points in One Source

Dupilumab Benefits Shown in Phase 3 Prurigo Nodularis Trials

The results "support the involvement of type 2 cytokines in driving PN disease pathogenesis and the targeting of the IL-4/IL-13 axis as a novel therapeutic paradigm" for PN, the authors write.